Eli Lilly Raises $8.94B in Debt, Acquires Kelonia for up to $7B to Boost Pipeline
summarizeSummary
Eli Lilly completed an $8.94 billion debt offering. The company also made several acquisitions in 2026, including Kelonia for up to $7 billion and Engage Biologics for up to $202 million, aimed at expanding its clinical pipelines and assets. This significant capital raise and M&A activity follows a period of strong operational performance and product development, including recent FDA approvals and robust Q1 2026 earnings. The debt financing supports Eli Lilly's aggressive strategy to expand its drug pipeline and manufacturing capabilities, as evidenced by its recent $27 billion investment in new plants.
At the time of this announcement, LLY was trading at $1,015.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $959.5B. The 52-week trading range was $623.78 to $1,133.95. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.